LU87150A1 - Nouveau carbamate de phenyle,sa preparation et son utilisation comme medicament - Google Patents

Nouveau carbamate de phenyle,sa preparation et son utilisation comme medicament Download PDF

Info

Publication number
LU87150A1
LU87150A1 LU87150A LU87150A LU87150A1 LU 87150 A1 LU87150 A1 LU 87150A1 LU 87150 A LU87150 A LU 87150A LU 87150 A LU87150 A LU 87150A LU 87150 A1 LU87150 A1 LU 87150A1
Authority
LU
Luxembourg
Prior art keywords
ethyl
compound
pharmaceutically acceptable
formula
free base
Prior art date
Application number
LU87150A
Other languages
English (en)
French (fr)
Original Assignee
Sandoz Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6322236&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU87150(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sandoz Sa filed Critical Sandoz Sa
Publication of LU87150A1 publication Critical patent/LU87150A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/44—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
LU87150A 1987-03-04 1988-03-02 Nouveau carbamate de phenyle,sa preparation et son utilisation comme medicament LU87150A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3706914 1987-03-04
DE3706914 1987-03-04

Publications (1)

Publication Number Publication Date
LU87150A1 true LU87150A1 (fr) 1988-11-17

Family

ID=6322236

Family Applications (2)

Application Number Title Priority Date Filing Date
LU87150A LU87150A1 (fr) 1987-03-04 1988-03-02 Nouveau carbamate de phenyle,sa preparation et son utilisation comme medicament
LU90297C LU90297I2 (fr) 1987-03-04 1998-10-07 Rivastigmine ses sels et dérivés pharmaceutiquement acceptables en particulier la rivastigmine sous forme d'hydrogénotartrate

Family Applications After (1)

Application Number Title Priority Date Filing Date
LU90297C LU90297I2 (fr) 1987-03-04 1998-10-07 Rivastigmine ses sels et dérivés pharmaceutiquement acceptables en particulier la rivastigmine sous forme d'hydrogénotartrate

Country Status (29)

Country Link
US (1) US5602176A (fi)
JP (3) JP2625478B2 (fi)
KR (1) KR0133686B1 (fi)
AT (1) AT394190B (fi)
AU (1) AU618949B2 (fi)
BE (1) BE1001467A3 (fi)
CA (1) CA1307003C (fi)
CH (1) CH675720A5 (fi)
CS (1) CS411091A3 (fi)
CY (1) CY1735A (fi)
DK (1) DK175762B1 (fi)
ES (1) ES2010527A6 (fi)
FI (1) FI89165C (fi)
FR (1) FR2611707B1 (fi)
GB (1) GB2203040C (fi)
GR (1) GR1000023B (fi)
HK (1) HK110093A (fi)
HU (1) HU201906B (fi)
IE (1) IE61714B1 (fi)
IL (1) IL85609A (fi)
IT (1) IT1219853B (fi)
LU (2) LU87150A1 (fi)
MY (1) MY103225A (fi)
NL (1) NL195004C (fi)
NZ (1) NZ223714A (fi)
PT (1) PT86875B (fi)
SA (1) SA93140384B1 (fi)
SE (1) SE8800731A0 (fi)
ZA (1) ZA881584B (fi)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL195004C (nl) * 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.
AU2224195A (en) * 1994-04-15 1995-11-10 Masaomi Iyo Medicinal composition for treating tardive dyskinesia and utilization thereof
EP0951284B1 (en) * 1996-12-18 2003-10-08 Teva Pharmaceutical Industries, Ltd. Phenylethylamine derivatives
EP0966435B1 (en) 1996-12-18 2005-04-06 Teva Pharmaceutical Industries, Ltd. Aminoindan derivatives
US6251938B1 (en) 1996-12-18 2001-06-26 Teva Pharmaceutical Industries, Ltd., Phenylethylamine derivatives
GB9800526D0 (en) * 1998-01-12 1998-03-11 Ciba Geigy Ag Organic compounds
US6316023B1 (en) * 1998-01-12 2001-11-13 Novartis Ag TTS containing an antioxidant
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
DE69923200T2 (de) 1998-10-01 2005-12-22 Novartis Ag Neue oral anzuwendende arzneizubereitungen für rivastigmine mit kontrollierter wirkstoffabgabe
US20040209849A1 (en) * 1998-11-27 2004-10-21 Sanochemia Pharmazeutika Aktiengesellschaft Use of effectors of the central cholinergic nervous system for treatment of delirium
CA2354035A1 (en) * 1998-12-11 2000-06-15 Bonnie Davis Use of acetylcholinesterase inhibitors on the modulation of the hypothalamic-pituitary-gonadal axis
GB9923045D0 (en) * 1999-09-29 1999-12-01 Novartis Ag New oral formulations
US6534541B1 (en) 1999-10-19 2003-03-18 Novartis Ag Treatment of ocular disorders
EP1284729A4 (en) * 2000-04-13 2007-12-19 Mayo Foundation REDUCTION AGENTS OF A (BETA) 42
US20040010038A1 (en) * 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
CZ20023555A3 (cs) 2002-10-24 2004-01-14 Léčiva, A.S. Způsob výroby (-)-(S)-3-[1-(dimethylamino)ethyl]fenyl-N-ethyl-N-methylkarbamátu
CA2502432A1 (en) * 2002-10-24 2004-05-06 Merz Pharma Gmbh & Co. Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
EP1651195A4 (en) * 2003-07-11 2007-10-03 Myriad Genetics Inc PHARMACEUTICAL PROCESSES, DOSIERSCHEMATA AND DOSAGE FORMS FOR THE TREATMENT OF ALZHEIMER DISEASE
KR20070085033A (ko) * 2003-10-21 2007-08-27 코루시드 파마슈티컬즈 인코포레이티드 콜린에스테라제를 억제하고 약리 활성제를 방출하는카르바모일 에스테르
GB2409453A (en) * 2003-12-24 2005-06-29 Generics Process for the preparation of aminoalkyl phenylcarbamates
US20070293538A1 (en) * 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
AU2005241023A1 (en) * 2004-04-29 2005-11-17 Keystone Retaining Wall Systems, Inc. Veneers for walls, retaining walls and the like
WO2006004201A1 (ja) * 2004-07-01 2006-01-12 Eisai R & D Management Co., Ltd. 神経再生促進剤
CA2618985A1 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
EP1856036B1 (en) * 2004-11-08 2016-12-14 Emcure Pharmaceuticals Limited An efficient method for preparation of (s)-3-[(1-dimethyl amino)ethyl]-phenyl-n-ethyl-n-methyl-carbamate
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
EA200800360A1 (ru) * 2005-07-22 2008-06-30 Мириад Дженетикс, Инк. Формуляции с высоким содержанием лекарства и дозированные формы
ES2267399B1 (es) 2005-08-04 2008-02-01 Ragactives, S.L. Procedimiento para la obtencion de carbamatos de fenilo.
EP2111901B1 (en) 2005-09-15 2012-02-01 Sony Computer Entertainment Inc. Obtaining input for controlling execution of a game program
TWI389709B (zh) * 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
ES2632638T3 (es) * 2005-12-09 2017-09-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Ladostigilo de baja dosis para el tratamiento de la deficiencia cognitiva
TW200744576A (en) * 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
US7767843B2 (en) * 2006-03-02 2010-08-03 Apotex Pharmachem Inc. Process for the preparation of phenylcarbamates
US20080033045A1 (en) * 2006-07-07 2008-02-07 Myriad Genetics, Incorporated Treatment of psychiatric disorders
DE602006015241D1 (de) * 2006-08-17 2010-08-12 Alembic Ltd Verbessertes verfahren zur herstellung von rivastigmin
WO2008037433A1 (en) 2006-09-29 2008-04-03 Synthon B.V. Process for making aminoalkylphenyl carbamates and intermediates therefor
CA2667553A1 (en) 2006-10-27 2008-05-02 Medivation Neurology, Inc. Methods and combination therapies for treating alzheimer's disease
EP1942100A1 (en) * 2007-01-04 2008-07-09 Krka Tovarna Zdravil, D.D., Novo Mesto Amorphous and crystalline forms of rivastigmine hydrogentartrate
EP2125709A2 (en) * 2007-02-02 2009-12-02 Colucid Pharmaceuticals, Inc. Compounds that inhibit cholinesterase
EP1980552A3 (en) 2007-04-10 2008-10-29 Dr. Reddy's Laboratories Ltd. A process for the preparation of rivastigmine or a salt thereof
CN101707952B (zh) * 2007-04-16 2012-08-29 上海特化医药科技有限公司 一种制备利伐斯的明的方法及其中间体
US7884121B2 (en) * 2007-06-11 2011-02-08 Apotex Pharmachem Inc. Process for the preparation of phenylcarbamates
US20090048229A1 (en) * 2007-07-18 2009-02-19 Rupniak Nadia M J Methods for promoting wakefulness
US8593728B2 (en) * 2009-02-19 2013-11-26 Toyota Motor Engineering & Manufacturing North America, Inc. Multilayer photonic structures
US20090082436A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched rivastigmine
CN101910110B (zh) * 2008-01-10 2013-05-22 上海医药工业研究院 利凡斯的明的制备方法、其中间体以及中间体的制备方法
EP2349976B1 (en) 2008-08-25 2012-12-26 Jubilant Life Sciences Limited A process for producing (s)-3-[(1-dimethylamino)ethyl]phenyl-n-ethyl-n-methyl-carbamate via novel intermediates
US20100087768A1 (en) * 2008-10-02 2010-04-08 Forlano Paula Transdermal drug delivery system for liquid active ingredient
GB0823554D0 (en) 2008-12-24 2009-01-28 Novartis Ag Process for the preparation of optically active compounds using transfer hydrogenation
CN101823970B (zh) * 2009-03-03 2013-05-08 江苏恩华药业股份有限公司 卡巴拉汀及其中间体的合成方法
US10076502B2 (en) 2009-12-22 2018-09-18 Luye Pharma Ag Transdermal therapeutic system for administering rivastigmine or derivatives thereof
DK2515886T3 (en) 2009-12-22 2018-06-14 Luye Pharma Ag Transdermal therapeutic system for administration of rivastigmine or derivatives thereof
ES2363395B1 (es) * 2010-01-20 2012-02-23 Farmalider, S.A. Composición farmacéutica l�?quida de rivastigmina o de una de sus sales de adición de �?cido para la administración por v�?a oral.
EP2533645B1 (en) * 2010-02-09 2016-07-27 The Johns Hopkins University Methods and compositions for improving cognitive function
CA2793580A1 (en) 2010-03-29 2011-10-06 Novartis Ag Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant
WO2011151669A1 (en) 2010-06-02 2011-12-08 Jubilant Life Sciences Limited Process for producing enantiomerically enriched isomer of 3-(1-aminoethyl) phenyl derivative and employing the same to produce rivastigmine or its pharmaceutically acceptable salt
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
EP2582799B1 (en) 2010-06-17 2017-12-20 Codexis, Inc. Biocatalysts and methods for the synthesis of (s)-3-(1-aminoethyl)-phenol
EP2640391B1 (en) 2010-11-15 2015-11-11 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
HUE027916T2 (en) 2010-12-14 2016-11-28 Acino Ag Transdermal therapeutic system for administration of an active ingredient
CN102786441B (zh) 2011-05-18 2013-11-13 浙江海正药业股份有限公司 利凡斯的明的制备方法、其中间体以及中间体的制备方法
US9585862B2 (en) 2011-05-20 2017-03-07 Sk Chemicals Co., Ltd. Patch containing rivastigmine
AR082640A1 (es) * 2011-08-25 2012-12-19 Amarin Technologies S A Un dispositivo para la administracion transdermal de compuestos alcalinos susceptibles a la degradacion en su forma no salificada
CN103796645B (zh) 2011-08-31 2017-06-20 东洋油墨Sc控股株式会社 贴剂
CN103073456B (zh) * 2011-10-26 2014-03-19 连云港润众制药有限公司 重酒石酸卡巴拉汀中间体的制备方法
EP2594261A1 (en) 2011-11-18 2013-05-22 Labtec GmbH Composition for transdermal administration of rivastigmine
WO2013142339A1 (en) 2012-03-23 2013-09-26 Novartis Ag Transdermal therapeutic system and method
ES2449215B1 (es) * 2012-09-17 2014-07-14 Galenicum Health S.L. Solución oral de (S)-3-[1-(dimetilamino)etil]fenil N-etil-N-metilcarbamato
KR20140038237A (ko) 2012-09-20 2014-03-28 에스케이케미칼주식회사 리바스티그민의 안정성이 개선된 의약품
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN103896787A (zh) * 2012-12-26 2014-07-02 江苏康倍得药业有限公司 一种卡巴拉汀前体[1-(3-甲氧基苯基)乙基]二甲胺的制备方法
WO2014111790A2 (en) 2013-01-15 2014-07-24 Zydus Technologies Limited Stable transdermal pharmaceutical drug delivery system comprising rivastigmine
EP2968237A4 (en) 2013-03-15 2016-08-31 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
AU2014228512A1 (en) 2013-03-15 2015-10-01 Agenebio, Inc. Methods and compositions for improving cognitive function
CN103319374B (zh) * 2013-06-09 2015-04-22 无锡佰翱得生物科学有限公司 一种(s)-卡巴拉汀的不对称合成方法
AU2014307803A1 (en) 2013-08-16 2016-03-10 Universiteit Maastricht Treatment of cognitive impairment with PDE4 inhibitor
EP4032889A1 (en) 2013-12-20 2022-07-27 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US10925834B2 (en) 2015-05-22 2021-02-23 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
US10815242B2 (en) 2015-06-19 2020-10-27 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
BR112019012821A2 (pt) 2016-12-19 2019-11-26 Agenebio Inc derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
EP3810611A4 (en) 2018-06-19 2022-03-30 Agenebio, Inc. BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS OF TREATING COGNITIVE IMPAIRMENT
KR20200035359A (ko) 2018-09-26 2020-04-03 캐딜라 파마슈티클즈 리미티드 리바스티그민 제조용 중간체의 합성
WO2024039886A1 (en) 2022-08-19 2024-02-22 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4469700A (en) * 1981-06-19 1984-09-04 Lowell M. Somers Benzoylecgonine or benzoylnorecgonine as active agents for the treatment of rheumatoid arthritis
IL74497A (en) * 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
NL195004C (nl) * 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.

Also Published As

Publication number Publication date
JP2859225B2 (ja) 1999-02-17
AU618949B2 (en) 1992-01-16
FI89165B (fi) 1993-05-14
IT8847693A0 (it) 1988-03-04
CH675720A5 (fi) 1990-10-31
FR2611707B1 (fr) 1990-04-20
AU1255488A (en) 1988-09-08
FI880972A (fi) 1988-09-05
GR880100125A (en) 1989-01-31
ATA55188A (de) 1991-08-15
PT86875A (pt) 1988-04-01
JPS63238054A (ja) 1988-10-04
CS411091A3 (en) 1992-12-16
IL85609A (en) 1992-07-15
BE1001467A3 (fr) 1989-11-07
DK112588A (da) 1988-09-05
IL85609A0 (en) 1988-08-31
HK110093A (en) 1993-10-29
GR1000023B (el) 1990-01-31
ZA881584B (en) 1989-11-29
CY1735A (en) 1994-06-03
IE61714B1 (en) 1994-11-30
IE880583L (en) 1988-09-04
NL195004C (nl) 2003-11-04
DK175762B1 (da) 2005-02-14
KR880011088A (ko) 1988-10-26
PT86875B (pt) 1992-05-29
FI880972A0 (fi) 1988-03-02
HUT49325A (en) 1989-09-28
GB2203040C (en) 2014-07-30
SE8800731L (sv) 1988-09-05
CA1307003C (en) 1992-09-01
NL195004B (nl) 2003-07-01
SE8800731A0 (sv) 1988-09-05
IT1219853B (it) 1990-05-24
US5602176A (en) 1997-02-11
SE8800731D0 (sv) 1988-03-02
KR0133686B1 (ko) 1998-04-21
GB8804888D0 (en) 1988-03-30
AT394190B (de) 1992-02-10
NL8800436A (nl) 1988-10-03
NZ223714A (en) 1994-05-26
LU90297I2 (fr) 1998-12-07
FI89165C (fi) 1993-08-25
JPH09165362A (ja) 1997-06-24
FR2611707A1 (fr) 1988-09-09
SA93140384B1 (ar) 2006-04-04
GB2203040B (en) 1990-10-24
DK112588D0 (da) 1988-03-02
GB2203040A (en) 1988-10-12
JP2625478B2 (ja) 1997-07-02
JPH09118617A (ja) 1997-05-06
ES2010527A6 (es) 1989-11-16
HU201906B (en) 1991-01-28
MY103225A (en) 1993-05-29

Similar Documents

Publication Publication Date Title
LU87150A1 (fr) Nouveau carbamate de phenyle,sa preparation et son utilisation comme medicament
KR100236562B1 (ko) 트라마돌 및 비-스테로이드성 소염제를 함유하는 조성물
US5691365A (en) Nicotinic receptor antagonists in the treatment of neuropharmacological disorders
Manoury et al. Synthesis of a series of compounds related to betaxolol, a new. beta. 1-adrenoceptor antagonist with a pharmacological and pharmacokinetic profile optimized for the treatment of chronic cardiovascular diseases
SK10912000A3 (sk) Farmaceuticky prijateľné soli a solváty (+)-(2s,3s)-2-(3-chlórfenyl)-3,5,5-trimetyl-2-morfolinolu, farmaceutický prostriedok s ich obsahom a ich použitie
JP2011126909A (ja) エキソ−ｓ−メカミラミン製剤および治療におけるその使用
EP1908461A1 (fr) Utilisation de l' énantiomère (1S, 2R) du milnacipran pour la préparation d' un médicament
HUE035105T2 (en) A composition comprising nicotine and opipramole and its use
PT867179E (pt) Composicao de esteres de l-dopa
JP2012246297A (ja) ニコチン様物質受容体のモジュレーターとしてのガランタミンおよびリコラミンの類似物
CH630068A5 (en) Process for the preparation of 4-hydroxyphenylalkanolamine derivatives
CH641759A5 (fr) Phenethanolamines et composition pharmaceutique antineoplastique les contenant.
CH683427A5 (fr) Composé d'isoquinoléine comme agents de blocage neuromusculaire.
BE1003959A5 (fr) Agent therapeutique pour le traitement de troubles associes a l'ischemie cerebrale.
US20090176835A1 (en) Pharmaceutical composition for suppression of the expression of atp citrate lyase and use thereof
NL195081C (nl) Fenylcarbamaat.
EP1406627B1 (fr) Derives de pyridin-2-yl-methylamine pour le traitement de la dependance aux opioides
FR2744364A1 (fr) Application d'ureidoacetamides a la preparation de medicaments destines au traitement de l'abus de drogues ou de substances donnant lieu a des pharmacomanies ou a un usage excessif
Musson Chemical and Biological Studies on 3-(2, 4, 5-trihydroxyphenyl)-2-methylalanine (6-hydroxy-[alpha]-methyldopa)
WO2005016331A1 (ja) Ｎ−（ベンゾイル）アミノ酸誘導体を有効成分とするニューロパシー性疼痛治療剤
Davis et al. The effect of the MAO-A selective inhibitor brofaromine on the plasma and urine concentrations of some biogenic amines and their acidic metabolites in bulimia nervosa
CZ20002690A3 (cs) Farmaceuticky přijatelné soli a solváty (+)- (2S,3S)-2-(3-chlorfenyl)-3,5,5-trimethyl-2- morfolinolu a farmaceutický prostředek
WO1997033582A1 (fr) Compositions d'antagonistes de site polyamine
BE889046A (fr) Nouveaux medicaments a base de 4-aryl-2 (h)-quinazolinones pour le traitement de la dysmenorrhee

Legal Events

Date Code Title Description
CCP Supplementary protection certificate

Free format text: 90297, EXPIRES: 20130302